BioSpace News Archive

Yemaachi, the company dedicated to advancing precision oncology research and care in Africa for the benefit of patients everywhere, recently shared findings from a sequencing study in an abstract and poster presentation at the 14th AORTIC International Conference on Cancer in Africa.

BioNxt Solutions Inc. is pleased to report on a successful CPHI pharma conference in Barcelona, Spain, recently attended by BioNxt’s European team.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today reported financial results and key business updates for the third quarter ended September 30, 2023.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023.

Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy.

Bristol Myers Squibb (NYSE: BMY) today announced that research across the company’s cardiovascular franchise will be presented at the American Heart Association’s (AHA) annual Scientific Sessions, taking place November 11-13, 2023 in Philadelphia, Pennsylvania.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023.

InflaRx N.V. (Nasdaq: IFRX) announced today that the first patient has been dosed in its Phase III study investigating the efficacy and safety of vilobelimab in ulcerative PG, a rare neutrophilic and inflammatory skin disease characterized by destructive, painful cutaneous ulcers.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced data was presented at Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting on Saturday, November 4, 2023.

Meilleur Technologies, Inc. today announced a research collaboration agreement with the National Institute of Aging (NIA)-sponsored multicenter study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).